The microbiome and emerging pathogens in cystic fibrosis and non-cystic fibrosis bronchiectasis

Seminars in Respiratory and Critical Care Medicine

Volumn 36, Issue 2, 2015, Pages 225-235

  Green, Heather ^a   Jones, Andrew M ^a  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

cystic fibrosis; emerging pathogens; microbiology; microbiome; non CF bronchiectasis

Indexed keywords

ACHROMOBACTER; ANAEROBE; ARTICLE; ATYPICAL MYCOBACTERIUM; BRONCHIECTASIS; BURKHOLDERIA; BURKHOLDERIA AMBIFARIA; BURKHOLDERIA CENOCEPACIA; BURKHOLDERIA CEPACIA; BURKHOLDERIA CEPACIA COMPLEX; BURKHOLDERIA CEPACIA INFECTION; BURKHOLDERIA DOLOSA; BURKHOLDERIA GLADIOLI; BURKHOLDERIA MULTIVORANS; BURKHOLDERIA PYRROCINIA; BURKHOLDERIA VIETNAMIENSIS; CYSTIC FIBROSIS; HUMAN; MICROBIOME; NON CYSTIC FIBROSIS BRONCHIECTASIS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; RALSTONIA; STENOTROPHOMONAS; STENOTROPHOMONAS MALTOPHILIA; ANAEROBIC BACTERIUM; CLASSIFICATION; COMPLICATION; FUNGUS; LUNG; MICROBIOLOGY; MICROFLORA; PATHOGENICITY; RADIOGRAPHY; RESPIRATORY TRACT INFECTION;

ACHROMOBACTER; BACTERIA, ANAEROBIC; BRONCHIECTASIS; BURKHOLDERIA; CYSTIC FIBROSIS; FUNGI; HUMANS; LUNG; MICROBIOTA; NONTUBERCULOUS MYCOBACTERIA; RALSTONIA; RESPIRATORY TRACT INFECTIONS; STENOTROPHOMONAS MALTOPHILIA;

EID: 84926202449     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0035-1546752     Document Type: Article

References (105)

1. Burkholder W. H. Sour skin, a bacterial rot of onion bulbs. Phytopathology: 1950; 40 115 118
2. Yabuuchi E., Kosako Y., Oyaizu H., et al. Proposal of Burkholderia gen. nov. and transfer of seven species of the genus Pseudomonas homology group II to the new genus, with the type species Burkholderia cepacia (Palleroni and Holmes 1981) comb. nov. Microbiol Immunol: 1992; 36 12 1251 1275
3. Vanlaere E., Lipuma J. J., Baldwin A., et al. Burkholderia latens sp. nov., Burkholderia diffusa sp. nov., Burkholderia arboris sp. nov., Burkholderia seminalis sp. nov. and Burkholderia metallica sp. nov., novel species within the Burkholderia cepacia complex. Int J Syst Evol Microbiol: 2008; 58 Pt 7 1580 1590
4. Vandamme P., Mahenthiralingam E., Holmes B., et al. Identification and population structure of Burkholderia stabilis sp. nov. (formerly Burkholderia cepacia genomovar IV). J Clin Microbiol: 2000; 38 3 1042 1047
5. Vandamme P., Holmes B., Vancanneyt M., et al. Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov. Int J Syst Bacteriol: 1997; 47 4 1188 1200
6. Peeters C., Zlosnik J. E., Spilker T., Hird T. J., LiPuma J. J., Vandamme P. Burkholderia pseudomultivorans sp. nov., a novel Burkholderia cepacia complex species from human respiratory samples and the rhizosphere. Syst Appl Microbiol: 2013; 36 7 483 489
7. Govan J. R., Hughes J. E., Vandamme P. Burkholderia cepacia: medical, taxonomic and ecological issues. J Med Microbiol: 1996; 45 6 395 407
8. Laraya-Cuasay L., Lipstein M., Huang N. Pseudomonas cepacia in the respiratory flora of patients with cystic fibrosis (CF). Pediatr Res: 1977; 11 502
9. Isles A., Maclusky I., Corey M., et al. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr: 1984; 104 2 206 210
10. Tablan O. C., Chorba T. L., Schidlow D. V., et al. Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome. J Pediatr: 1985; 107 3 382 387
11. Muhdi K., Edenborough F. P., Gumery L., et al. Outcome for patients colonised with Burkholderia cepacia in a Birmingham adult cystic fibrosis clinic and the end of an epidemic. Thorax: 1996; 51 4 374 377
12. LiPuma J. J., Dasen S. E., Nielson D. W., Stern R. C., Stull T. L. Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis. Lancet: 1990; 336 8723 1094 1096
13. Govan J. R., Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev: 1996; 60 3 539 574
14. Govan J. R., Brown P. H., Maddison J., et al. Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet: 1993; 342 8862 15 19
15. Ledson M. J., Gallagher M. J., Corkill J. E., Hart C. A., Walshaw M. J. Cross infection between cystic fibrosis patients colonised with Burkholderia cepacia. Thorax: 1998; 53 5 432 436
16. Mahenthiralingam E., Campbell M. E., Henry D. A., Speert D. P. Epidemiology of Burkholderia cepacia infection in patients with cystic fibrosis: analysis by randomly amplified polymorphic DNA fingerprinting. J Clin Microbiol: 1996; 34 12 2914 2920
17. Speert D. P. Advances in Burkholderia cepacia complex. Paediatr Respir Rev: 2002; 3 3 230 235
18. Drevinek P., Mahenthiralingam E. Burkholderia cenocepacia in cystic fibrosis: epidemiology and molecular mechanisms of virulence. Clin Microbiol Infect: 2010; 16 7 821 830
19. Coenye T., Spilker T., Van Schoor A., LiPuma J. J., Vandamme P. Recovery of Burkholderia cenocepacia strain PHDC from cystic fibrosis patients in Europe. Thorax: 2004; 59 11 952 954
20. Jones A. M., Dodd M. E., Govan J. RW., et al. Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis. Thorax: 2004; 59 11 948 951
21. Courtney J. M., Dunbar K. E., McDowell A., et al. Clinical outcome of Burkholderia cepacia complex infection in cystic fibrosis adults. J Cyst Fibros: 2004; 3 2 93 98
22. Boussaud V., Guillemain R., Grenet D., et al. Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia cepacia complex: results from two French centres. Thorax: 2008; 63 8 732 737
23. Turton J. F., Kaufmann M. E., Mustafa N., Kawa S., Clode F. E., Pitt T. L. Molecular comparison of isolates of Burkholderia multivorans from patients with cystic fibrosis in the United Kingdom. J Clin Microbiol: 2003; 41 12 5750 5754
24. Baldwin A., Mahenthiralingam E., Drevinek P., et al. Environmental Burkholderia cepacia complex isolates in human infections. Emerg Infect Dis: 2007; 13 3 458 461
25. Whiteford M. L., Wilkinson J. D., McColl J. H., et al. Outcome of Burkholderia (Pseudomonas) cepacia colonisation in children with cystic fibrosis following a hospital outbreak. Thorax: 1995; 50 11 1194 1198
26. Mahenthiralingam E., Coenye T., Chung J. W., et al. Diagnostically and experimentally useful panel of strains from the Burkholderia cepacia complex. J Clin Microbiol: 2000; 38 2 910 913
27. Biddick R., Spilker T., Martin A., LiPuma J. J. Evidence of transmission of Burkholderia cepacia, Burkholderia multivorans and Burkholderia dolosa among persons with cystic fibrosis. FEMS Microbiol Lett: 2003; 228 1 57 62
28. Mahenthiralingam E., Vandamme P., Campbell M. E., et al. Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans. Clin Infect Dis: 2001; 33 9 1469 1475
29. Silva I. N., Ferreira A. S., Becker J. D., et al. Mucoid morphotype variation of Burkholderia multivorans during chronic cystic fibrosis lung infection is correlated with changes in metabolism, motility, biofilm formation and virulence. Microbiology: 2011; 157 Pt 11 3124 3137
30. Schmerk C. L., Valvano M. A. Burkholderia multivorans survival and trafficking within macrophages. J Med Microbiol: 2013; 62 Pt 2 173 184
31. Kalish L. A., Waltz D. A., Dovey M., et al. Impact of Burkholderia dolosa on lung function and survival in cystic fibrosis. Am J Respir Crit Care Med: 2006; 173 4 421 425
32. Blackburn L., Brownlee K., Conway S., Denton M. 'Cepacia syndrome' with Burkholderia multivorans, 9 years after initial colonization. J Cyst Fibros: 2004; 3 2 133 134
33. Kennedy M. P., Coakley R. D., Donaldson S. H., et al. Burkholderia gladioli: five year experience in a cystic fibrosis and lung transplantation center. J Cyst Fibros: 2007; 6 4 267 273
34. Murray S., Charbeneau J., Marshall B. C., LiPuma J. J. Impact of burkholderia infection on lung transplantation in cystic fibrosis. Am J Respir Crit Care Med: 2008; 178 4 363 371
35. Church A. C., Sivasothy P., Parmer J., Foweraker J. Mediastinal abscess after lung transplantation secondary to Burkholderia gladioli infection. J Heart Lung Transplant: 2009; 28 5 511 514
36. Quon B. S., Reid J. D., Wong P., et al. Burkholderia gladioli - a predictor of poor outcome in cystic fibrosis patients who receive lung transplants? A case of locally invasive rhinosinusitis and persistent bacteremia in a 36-year-old lung transplant recipient with cystic fibrosis. Can Respir J: 2011; 18 4 e64 e65
37. Brizendine K. Fatal Burkholderia gladioli infection misidentified as Empedobacter brevis in a lung transplant recipient with cystic fibrosis. Baddley, JW Pappas, PG Leon. Transpl Infect Dis: 2012; 14 4 13 18
38. Denton M., Kerr K. G. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev: 1998; 11 1 57 80
39. Blessing J., Walker J. Pseudomonas cepacia and maltophilia in the cystic-fibrosis patient. Am Rev Respir Dis: 1979; 119 262
40. Munter R. G., Yinnon A. M., Schlesinger Y., Hershko C. Infective endocarditis due to Stenotrophomonas (Xanthomonas) maltophilia. Eur J Clin Microbiol Infect Dis: 1998; 17 5 353 356
41. Gopalakrishnan R., Hawley H. B., Czachor J. S., Markert R. J., Bernstein J. M. Stenotrophomonas maltophilia infection and colonization in the intensive care units of two community hospitals: a study of 143 patients. Heart Lung: 1999; 28 2 134 141
42. San Gabriel P., Zhou J., Tabibi S., Chen Y., Trauzzi M., Saiman L. Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis. Antimicrob Agents Chemother: 2004; 48 1 168 171
43. Cescutti P., Cuzzi B., Liut G., Segonds C., Di Bonaventura G., Rizzo R. A novel highly charged exopolysaccharide produced by two strains of Stenotrophomonas maltophilia recovered from patients with cystic fibrosis. Carbohydr Res: 2011; 346 13 1916 1923
44. Pompilio A., Pomponio S., Crocetta V., et al. Phenotypic and genotypic characterization of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis: genome diversity, biofilm formation, and virulence. BMC Microbiol: 2011; 11 1 159
45. Dalboge C. S., Hansen C. R., Pressler T., Hoiby N., Johansen H. K. Chronic pulmonary infection with Stenotrophomonas maltophilia and lung function in patients with cystic fibrosis. J Cyst Fibros: 2011; 10 5 318 325
46. Goss C. H., Otto K., Aitken M. L., Rubenfeld G. D. Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis. Am J Respir Crit Care Med: 2002; 166 3 356 361
47. Marchac V., Equi A., Le Bihan-Benjamin C., Hodson M., Bush A. Case-control study of Stenotrophomonas maltophilia acquisition in cystic fibrosis patients. Eur Respir J: 2004; 23 1 98 102
48. Waters V., Atenafu E. G., Lu A., Yau Y., Tullis E., Ratjen F. Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients. J Cyst Fibros: 2013; 12 5 482 486
49. Waters V., Yau Y., Prasad S., et al. Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. Am J Respir Crit Care Med: 2011; 183 5 635 640
50. Goss C. H., Mayer-Hamblett N., Aitken M. L., Rubenfeld G. D., Ramsey B. W. Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis. Thorax: 2004; 59 11 955 959
51. Talmaciu I., Varlotta L., Mortensen J., Schidlow D. V. Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis. Pediatr Pulmonol: 2000; 30 1 10 15
52. Krzewinski J. W., Nguyen C. D., Foster J. M., Burns J. L. Use of random amplified polymorphic DNA PCR to examine epidemiology of Stenotrophomonas maltophilia and Achromobacter (Alcaligenes) xylosoxidans from patients with cystic fibrosis. J Clin Microbiol: 2001; 39 10 3597 3602
53. Marzuillo C., De Giusti M., Tufi D., et al. Molecular Characterization of Stenotrophomonas maltophilia isolates from cystic fibrosis patients and the hospital environment. Infect Control Hosp Epidemiol: 2009; 30 8 753 758
54. Vandamme P., Moore E. RB, Cnockaert M., et al. Achromobacter animicus sp. nov., Achromobacter mucicolens sp. nov., Achromobacter pulmonis sp. nov. and Achromobacter spiritinus sp. nov., from human clinical samples. Syst Appl Microbiol: 2013; 36 1 1 10
55. Vandamme P., Moore E. RB, Cnockaert M., et al. Classification of Achromobacter genogroups 2, 5, 7 and 14 as Achromobacter insuavis sp. nov., Achromobacter aegrifaciens sp. nov., Achromobacter anxifer sp. nov. and Achromobacter dolens sp. nov., respectively. Syst Appl Microbiol: 2013; 36 7 474 482
56. Ridderberg W., Wang M., Norskov-Lauritsen N. Multilocus sequence analysis of isolates of Achromobacter from patients with cystic fibrosis reveals infecting species other than Achromobacter xylosoxidans. J Clin Microbiol: 2012; 50 8 2688 2694
57. Spilker T., Vandamme P., Lipuma J. J. A multilocus sequence typing scheme implies population structure and reveals several putative novel Achromobacter species. J Clin Microbiol: 2012; 50 9 3010 3015
58. Spilker T., Vandamme P., Lipuma J. J. Identification and distribution of Achromobacter species in cystic fibrosis. J Cyst Fibros: 2013; 12 3 298 301
59. Cystic Fibrosis Foundation Patient Registry; 2005 Annual Data Report
60. Cystic Fibrosis Foundation Patient Registry; 2011 Annual Data Report
61. Cystic Fibrosis Foundation Patient Registry; 2012 Annual Data Report
62. De Baets F., Schelstraete P., Van Daele S., Haerynck F., Vaneechoutte M. Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance. J Cyst Fibros: 2007; 6 1 75 78
63. Saiman L., Chen Y., Tabibi S., et al. Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. J Clin Microbiol: 2001; 39 11 3942 3945
64. Raso T., Bianco O., Grosso B., Zucca M., Savoia D. Achromobacter xylosoxidans respiratory tract infections in cystic fibrosis patients. APMIS: 2008; 116 9 837 841
65. Lambiase A., Catania M. R., Del Pezzo M., et al. Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis: 2011; 30 8 973 980
66. Trancassini M., Iebba V., Citerà N., et al. Outbreak of Achromobacter xylosoxidans in an Italian Cystic fibrosis center: genome variability, biofilm production, antibiotic resistance, and motility in isolated strains. Front Microbiol: 2014; 5 April 138
67. Hansen C. R., Pressler T., Nielsen K. G., Jensen PO, Bjarnsholt T., Hoiby N. Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients. J Cyst Fibros: 2010; 9 1 51 58
68. Ronne Hansen C., Pressler T., Hoiby N., Gormsen M. Chronic infection with Achromobacter xylosoxidans in cystic fibrosis patients; a retrospective case control study. J Cyst Fibros: 2006; 5 4 245 251
69. Tan K., Conway S. P., Brownlee K. G., Etherington C., Peckham D. G. Alcaligenes infection in cystic fibrosis. Pediatr Pulmonol: 2002; 34 2 101 104
70. Kanellopoulou M., Pournaras S., Iglezos H., Skarmoutsou N., Papafrangas E., Maniatis A. N. Persistent colonization of nine cystic fibrosis patients with an Achromobacter (Alcaligenes) xylosoxidans clone. Eur J Clin Microbiol Infect Dis: 2004; 23 4 336 339
71. Van Daele S., Verhelst R., Claeys G., et al. Shared genotypes of Achromobacter xylosoxidans strains isolated from patients at a cystic fibrosis rehabilitation center. J Clin Microbiol: 2005; 43 6 2998 3002
72. Pereira R. HV, Carvalho-Assef A. P., Albano R. M., et al. Achromobacter xylosoxidans: characterization of strains in Brazilian cystic fibrosis patients. J Clin Microbiol: 2011; 49 10 3649 3651
73. Hansen C. R., Pressler T., Ridderberg W., Johansen H. K., Skov M. Achromobacter species in cystic fibrosis: cross-infection caused by indirect patient-to-patient contact. J Cyst Fibros: 2013; 12 6 609 615
74. Dunne W. M. Jr, Maisch S. Epidemiological investigation of infections due to Alcaligenes species in children and patients with cystic fibrosis: use of repetitive-element-sequence polymerase chain reaction. Clin Infect Dis: 1995; 20 4 836 841
75. Coenye T., Falsen E., Hoste B., et al. Description of Pandoraea gen. nov. with Pandoraea apista sp. nov., Pandoraea pulmonicola sp. nov., Pandoraea pnomenusa sp. nov., Pandoraea sputorum sp. nov. and Pandoraea norimbergensis comb. nov. Int J Syst Evol Microbiol: 2000; 50 Pt 2 887 899
76. Pimentel J. D., MacLeod C. Misidentification of Pandoraea sputorum isolated from sputum of a patient with cystic fibrosis and review of Pandoraea species infections in transplant patients. J Clin Microbiol: 2008; 46 9 3165 3168
77. Martínez-Lamas L., Rabade Castedo C., Martín Romero Domínguez M., Barbeito Castiñeiras G., Palacios Bartolomé A., Pérez Del Molino Bernal M. L. [Pandoraea sputorum colonization in a patient with cystic fibrosis]. Arch Bronconeumol: 2011; 47 11 571 574
78. Johnson L. N., Han J. Y., Moskowitz S. M., Burns J. L., Qin X., Englund J. A. Pandoraea bacteremia in a cystic fibrosis patient with associated systemic illness. Pediatr Infect Dis J: 2004; 23 9 881 882
79. Jorgensen I. M., Johansen H. K., Frederiksen B., et al. Epidemic spread of Pandoraea apista, a new pathogen causing severe lung disease in cystic fibrosis patients. Pediatr Pulmonol: 2003; 36 5 439 446
80. Atkinson R. M., Lipuma J. J., Rosenbluth D. B., Dunne W. M. Jr. Chronic colonization with Pandoraea apista in cystic fibrosis patients determined by repetitive-element-sequence PCR. J Clin Microbiol: 2006; 44 3 833 836
81. Caraher E., Collins J., Herbert G., et al. Evaluation of in vitro virulence characteristics of the genus Pandoraea in lung epithelial cells. J Med Microbiol: 2008; 57 Pt 1 15 20
82. Costello A., Herbert G., Fabunmi L., et al. Virulence of an emerging respiratory pathogen, genus Pandoraea, in vivo and its interactions with lung epithelial cells. J Med Microbiol: 2011; 60 Pt 3 289 299
83. Daneshvar M. I., Hollis D. G., Steigerwalt A. G., et al. Assignment of CDC weak oxidizer group 2 (WO-2) to the genus Pandoraea and characterization of three new Pandoraea genomospecies. J Clin Microbiol: 2001; 39 5 1819 1826
84. Stryjewski M. E., LiPuma J. J., Messier R. H. Jr, Reller L. B., Alexander B. D. Sepsis, multiple organ failure, and death due to Pandoraea pnomenusa infection after lung transplantation. J Clin Microbiol: 2003; 41 5 2255 2257
85. Yabuuchi E., Kosako Y., Yano I., Hotta H., Nishiuchi Y. Transfer of two Burkholderia and an Alcaligenes species to Ralstonia gen. Nov.: Proposal of Ralstonia pickettii (Ralston, Palleroni and Doudoroff 1973) comb. Nov., Ralstonia solanacearum (Smith 1896) comb. Nov. and Ralstonia eutropha (Davis 1969) comb. Nov. Microbiol Immunol: 1995; 39 11 897 904
86. Coenye T., Vandamme P., LiPuma J. J. Infection by Ralstonia species in cystic fibrosis patients: identification of R. pickettii and R. mannitolilytica by polymerase chain reaction. Emerg Infect Dis: 2002; 8 7 692 696
87. Coenye T., Spilker T., Reik R., Vandamme P., Lipuma J. J. Use of PCR analyses to define the distribution of Ralstonia species recovered from patients with cystic fibrosis. J Clin Microbiol: 2005; 43 7 3463 3466
88. Daxboeck F., Stadler M., Assadian O., Marko E., Hirschl A. M., Koller W. Characterization of clinically isolated Ralstonia mannitolilytica strains using random amplification of polymorphic DNA (RAPD) typing and antimicrobial sensitivity, and comparison of the classification efficacy of phenotypic and genotypic assays. J Med Microbiol: 2005; 54 Pt 1 55 61
89. Lipuma J. J. The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev: 2010; 23 2 299 323
90. Burns J. L., Emerson J., Stapp J. R., et al. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis: 1998; 27 1 158 163
91. Tunney M. M., Field T. R., Moriarty T. F., et al. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med: 2008; 177 9 995 1001
92. Worlitzsch D., Rintelen C., Böhm K., et al. Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients. Clin Microbiol Infect: 2009; 15 5 454 460
93. Parkins M. D., Sibley C. D., Surette M. G., Rabin H. R. The Streptococcus milleri group-an unrecognized cause of disease in cystic fibrosis: a case series and literature review. Pediatr Pulmonol: 2008; 43 5 490 497
94. Field T. R., Sibley C. D., Parkins M. D., Rabin H. R., Surette M. G. The genus Prevotella in cystic fibrosis airways. Anaerobe: 2010; 16 4 337 344
95. Ulrich M., Beer I., Braitmaier P., et al. Relative contribution of Prevotella intermedia and Pseudomonas aeruginosa to lung pathology in airways of patients with cystic fibrosis. Thorax: 2010; 65 11 978 984
96. Duan K., Dammel C., Stein J., Rabin H., Surette M. G. Modulation of Pseudomonas aeruginosa gene expression by host microflora through interspecies communication. Mol Microbiol: 2003; 50 5 1477 1491
97. Tunney M. M., Klem E. R., Fodor A. A., et al. Use of culture and molecular analysis to determine the effect of antibiotic treatment on microbial community diversity and abundance during exacerbation in patients with cystic fibrosis. Thorax: 2011; 66 7 579 584
98. Zemanick E. T., Harris J. K., Wagner B. D., et al. Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations. PLoS ONE: 2013; 8 4 e62917
99. Tunney M. M., Einarsson G. G., Wei L., et al. Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care Med: 2013; 187 10 1118 1126
100. Zhao J., Schloss P. D., Kalikin L. M., et al. Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci U S A: 2012; 109 15 5809 5814
101. Bittar F., Richet H., Dubus J-C., et al. Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients. PLoS ONE: 2008; 3 8 e2908
102. Rogers G. B., Carroll M. P., Serisier D. J., Hockey P. M., Jones G., Bruce K. D. characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16s ribosomal DNA terminal restriction fragment length polymorphism profiling. J Clin Microbiol: 2004; 42 11 5176 5183
103. Cox M. J., Allgaier M., Taylor B., et al. Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients. PLoS ONE: 2010; 5 6 e11044
104. Fodor A. A., Klem E. R., Gilpin D. F., et al. The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations. PLoS ONE: 2012; 7 9 e45001
105. UK Cystic Fibrosis Registry Annual Data Report; 2012